Hot Features
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expres... Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0048 | 0.809443507589 | 0.593 | 0.7 | 0.5601 | 2691448 | 0.63523753 | CS |
| 4 | -0.8622 | -59.0547945205 | 1.46 | 1.51 | 0.5451 | 4836607 | 0.63323436 | CS |
| 12 | -1.9122 | -76.1832669323 | 2.51 | 3.12 | 0.5451 | 2079667 | 1.08445232 | CS |
| 26 | -1.0122 | -62.8695652174 | 1.61 | 3.62 | 0.5451 | 1665736 | 1.62157429 | CS |
| 52 | -0.0522 | -8.03076923077 | 0.65 | 3.62 | 0.5451 | 1063504 | 1.53399342 | CS |
| 156 | -0.8622 | -59.0547945205 | 1.46 | 3.62 | 0.49 | 517457 | 1.51344337 | CS |
| 260 | -3.8422 | -86.536036036 | 4.44 | 10.87 | 0.47 | 762721 | 2.92359509 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.